Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K38/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.20220249575FORMULATION AND TREATMENT FOR OPHTHALMIC DISORDERS
US 11.08.2022
Int.Class A61K 35/51
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
48Reproductive organs
51Umbilical cord; Umbilical cord blood; Umbilical stem cells
Appl.No 17394628 Applicant AVAV LABS LLC Inventor Philipp R. VITTI

The disclosure provides therapeutic ophthalmic formulations, kits, and uses thereof in the treatment of eye pathologies.

2.202022103409Formulierung eines Nanotechnologie-basierten Liefersystems von Nano-Trägern zu Zellen des Immunsystems
DE 11.08.2022
Int.Class A61K 38/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
Appl.No 202022103409 Applicant Autade Kalyani Inventor

Eine Formulierung, die auf Nanotechnologie-Abgabe von Nanoträgern an Zellen des Immunsystems basiert, umfassend: eine erste Nano-Träger-Liganden-Zusammensetzung, die aus einem Kohlenhydrat und ähnlichen Resten besteht, die in der Lage sind, eine angeborene Immunantwort für ein Zellsystem zu stimulieren; einen zweiten Nano-Carrier-Liganden, der aus einem T-Zellen-Helferpeptid besteht; einen dritten Nano-Trägerliganden, der ein Gefahrensignal umfasst, das aus Endotoxinen, Hitzeschockproteinen, Nukleotiden, reaktiven Sauerstoffzwischenprodukten, Abbauprodukten der extrazellulären Matrix besteht; und wobei die Nano-Träger-Liganden-Zusammensetzung kovalent an den Kern gebunden ist, wobei die Nano-Träger-Liganden-Zusammensetzung eine Kohlenhydrateinheit umfasst.

3.WO/2022/167978OXYTOCIN READY TO INFUSE DOSAGE FORM
WO 11.08.2022
Int.Class A61K 38/095
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
08Peptides having 5 to 11 amino acids
095Oxytocins; Vasopressins; Related peptides
Appl.No PCT/IB2022/050956 Applicant SUN PHARMACEUTICAL INDUSTRIES LIMITED Inventor KUMAR, Samarth
The present disclosure relates to a ready-to-use or a ready to administer parenteral dosage form of oxytocin or a pharmaceutically acceptable salt thereof comprising a ready-to-infuse, stable aqueous solution of oxytocin or a pharmaceutically acceptable salt thereof. The solution can be administered to a patient in need thereof without manipulations in terms of its concentration and is stable for a prolonged period of time.
4.WO/2022/168113ADMINISTRATION METHOD OF A CHEMOTHERAPEUTIC AGENT
WO 11.08.2022
Int.Class A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
Appl.No PCT/IN2022/050079 Applicant MADHU, Suchit Inventor MADHU, Suchit
The present invention provides an administration method of a chemotherapeutic agent preferably Stiripentol for the treatment of solid and blood cancer. The present chemotherapeutic agent is target specific and substantially reduces the growth of the cancer cells. The target specific administration of the said Stiripentol inhibits the production of lactate dehydrogenase, to reduce the growth of the cancer cells. Further the present chemotherapeutic agent substantially reduces the cell viability, and the proliferation activity of the cancer cells.
5.WO/2022/170033ENGINEERED NATURAL LIGAND-BASED CAR: DIRECTED EVOLUTION OF THE STRESS-RECEPTOR NKP30
WO 11.08.2022
Int.Class A61K 38/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
Appl.No PCT/US2022/015214 Applicant THE TRUSTEES OF DARTMOUTH COLLEGE Inventor BUTLER, Savannah, E.
Directed evolution using yeast display was employed to isolate novel NKp3O variants that bind to B7H6 with higher affinity compared to the native receptor but retain its fast association and dissociation profile. Two variants, CC3 and CCS, were expressed as soluble Fc-fusion proteins and CARs containing CD28 and CD3ζ intracellular domains. These Fc fusion protein forms of NKp30 and its variants were better able to bind tumor cells expressing low levels of B7H6 than TZ47, and exhibited improved in vitro tumor cell killing relative to NKp30. Also, CAR T cells expressing the engineered variants produced unique cytokine signatures in response to multiple tumor types expressing B7H6 compared to both NKp30 and TZ47. These findings suggest that natural CAR receptors can be fine-tuned to produce more desirable signaling outputs while maintaining evolutionary advantages in ligand recognition relative to scFvs.
6.WO/2022/170108PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF IN PREVENTION OF RADIATION INJURY
WO 11.08.2022
Int.Class A61K 38/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
12Cyclic peptides
Appl.No PCT/US2022/015329 Applicant AILERON THERAPEUTICS, INC. Inventor VUKOVIC, Vojislav
The present disclosure describes methods of using peptidomimetic macrocycles in radiation therapy treatment, or prevention of or amelioration from disorders caused by exposure to acute radiation. In some embodiments, the peptidomimetic macrocycle can mitigate an adverse or side effect of radiation, including, for example, weight loss.
7.WO/2022/170063IL-15 FUSION PROTEINS AND METHODS OF MAKING AND USING SAME
WO 11.08.2022
Int.Class A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
Appl.No PCT/US2022/015271 Applicant SALUBRIS BIOTHERAPEUTICS, INC. Inventor LI, John
The disclosure provides recombinant fusion proteins comprising an antigen binding domain specific for CTLA-4, an IL-15Ra sushi domain and IL-15. The disclosure further provides methods of using these recombinant fusion proteins in the treatment of cancer.
8.WO/2022/170093COMPOSITIONS AND METHODS FOR TREATING WITH CAR CELLS
WO 11.08.2022
Int.Class A61K 35/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
Appl.No PCT/US2022/015307 Applicant UNIVERSITY OF UTAH RESEARCH FOUNDATION Inventor ATANACKOVIC, Djordje
Disclosed are CAR polypeptides comprising a target specific receptor and a death domain. Disclosed are CAR polypeptides comprising a LINGO 1 antigen binding domain, a transmembrane domain, and an intracellular signaling domain. Disclosed are CAR cells comprising one or more of the disclosed CAR polypeptides. Disclosed are cells comprising an altered α4β1 integrin. Disclosed are methods of treating comprising administering one or more of the disclosed cells to a subject in need thereof.
9.20220249689PROTEIN-ENCLOSING POLYMERIC MICELLE
US 11.08.2022
Int.Class A61K 47/69
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
69the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
Appl.No 17623144 Applicant THE UNIVERSITY OF TOKYO Inventor Horacio CABRAL

The present invention provides a polymeric complex comprising a protein and a block copolymer represented by the following formula (1).

embedded image

10.20220249767METHOD FOR TREATMENT OF NEUROCOGNITIVE DECLINE
US 11.08.2022
Int.Class A61M 5/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
5Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
14Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
Appl.No 17592723 Applicant INVICTUS HEALTH, INC. Inventor Jeffrey I. Haugland

A method for treating a patient with a neurodegenerative disease including performing Ketamine Infusion Therapy on the patient, performing hyperbaric oxygen therapy on the patient, intranasally infusing plasma into the patient, and intranasally infusing diluted insulin into the patient. Performing hyperbaric oxygen therapy on the patient may include placing the patient into a hyperbaric chamber, sealing and pressurizing the hyperbaric chamber, and pumping oxygen into the hyperbaric chamber while it is pressurized. Before intranasally infusing plasma into the patient, the method may include drawing blood from the patient and centrifugally extracting the plasma from the drawn blood, such as platelet rich plasma (PRP). Before drawing blood from the patient, the method may include intravenously injecting the patient with supplements, such as a combination of magnesium, calcium, B-vitamins, Vitamin C, nicotinamide adenine dinucleotide (NAD+), and Glutathione.